CeriBell (NASDAQ:CBLL) Hits New 1-Year High Following Analyst Upgrade

CeriBell (NASDAQ:CBLL) shares hit a new 52-week high during trading on Monday after TD Cowen raised their price target on the stock from $31.00 to $36.00. TD Cowen currently has a buy rating on the stock. CeriBell traded as high as $31.82 and last traded at $31.82, with a volume of 9376 shares. The stock had previously closed at $30.24.

Several other analysts have also issued reports on CBLL. William Blair initiated coverage on CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating for the company. JPMorgan Chase & Co. initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Monday. Canaccord Genuity Group initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, Bank of America initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $32.60.

CeriBell Stock Performance

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million. Research analysts predict that CeriBell will post -2.46 EPS for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.